CN114380915A - 抗cd73的抗体及其用途 - Google Patents
抗cd73的抗体及其用途 Download PDFInfo
- Publication number
- CN114380915A CN114380915A CN202110273227.3A CN202110273227A CN114380915A CN 114380915 A CN114380915 A CN 114380915A CN 202110273227 A CN202110273227 A CN 202110273227A CN 114380915 A CN114380915 A CN 114380915A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 39
- 150000001413 amino acids Chemical class 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 45
- 238000009739 binding Methods 0.000 claims description 41
- 230000027455 binding Effects 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 39
- 230000035772 mutation Effects 0.000 claims description 38
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 37
- 206010016654 Fibrosis Diseases 0.000 claims description 37
- 239000012634 fragment Substances 0.000 claims description 37
- 229920001184 polypeptide Polymers 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 230000004761 fibrosis Effects 0.000 claims description 34
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 238000003780 insertion Methods 0.000 claims description 32
- 230000037431 insertion Effects 0.000 claims description 32
- 238000006467 substitution reaction Methods 0.000 claims description 32
- 210000000056 organ Anatomy 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 210000004408 hybridoma Anatomy 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 108020001507 fusion proteins Proteins 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 14
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 229940126586 small molecule drug Drugs 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
- 102000045309 human NT5E Human genes 0.000 claims description 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 6
- 210000000795 conjunctiva Anatomy 0.000 claims description 6
- 231100000241 scar Toxicity 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims description 4
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 claims description 4
- 101710138871 Ig gamma-1 chain C region Proteins 0.000 claims description 4
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims description 4
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims description 4
- 101150111584 RHOA gene Proteins 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 3
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 3
- 201000002154 Pterygium Diseases 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 206010050207 Skin fibrosis Diseases 0.000 claims description 3
- 229960005370 atorvastatin Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 229960005110 cerivastatin Drugs 0.000 claims description 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960003765 fluvastatin Drugs 0.000 claims description 3
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 229960002797 pitavastatin Drugs 0.000 claims description 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 3
- 229960002965 pravastatin Drugs 0.000 claims description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 229960000672 rosuvastatin Drugs 0.000 claims description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 101150045565 Socs1 gene Proteins 0.000 claims description 2
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 claims description 2
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 102100031168 CCN family member 2 Human genes 0.000 claims 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 12
- 229960005305 adenosine Drugs 0.000 description 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 10
- 239000000562 conjugate Substances 0.000 description 10
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 10
- 229960002591 hydroxyproline Drugs 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 101150078577 Adora2b gene Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 108010006654 Bleomycin Proteins 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229960001561 bleomycin Drugs 0.000 description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 3
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 2
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
- 229960002329 methacholine Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229940059392 oleclumab Drugs 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009092 tissue dysfunction Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101150101087 Nt5e gene Proteins 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000006679 metabolic signaling pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000023750 transforming growth factor beta production Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
本发明涉及抗CD73抗体及其应用。具体地,所述抗体的重链可变区包含氨基酸序列如SEQ ID NOs:15‑17所示的HCDR1‑HCDR3;并且所述抗体的轻链可变区包含氨基酸序列如SEQ ID NOs:18‑20所示的LCDR1‑LCDR3。
Description
技术领域
本发明涉及免疫学领域。具体地,涉及抗CD73抗体及其用途。
背景技术
胞外-5′-核苷酸酶(Ecto-5’-nucleotidase),即CD73蛋白,是NT5E基因编码的一种蛋白分子量为70KD的多功能糖蛋白,其通过糖基磷脂酰肌醇(glyocsyl phosphatidylinositol,GPI)锚定于细胞膜上(Zimmermann H.Biochem J.1992;285:345-365)。
CD73广泛分布在人体组织细胞表面,在免疫细胞表面亦广泛表达,如树突细胞、调节型T细胞(Treg)、自然杀伤细胞(NK细胞)、髓系起源的抑制细胞(MDSC)等。
CD73既有水解酶活性,又有非水解酶作用。CD73的酶与非酶功能的一个免疫抑制机制是由CD73-腺苷(Adenosine)代谢信号通路介导的,CD73上游的CD39可以催化ATP产生腺苷单磷酸(AMP),所产生的AMP被CD73转化为腺苷,而腺苷会结合下游的腺苷受体(A2AR),A2AR通过激活蛋白激酶A(PKA)和Csk激酶,抑制LCK、MAPK、PKC等一系列与免疫激活相关的信号通路,抑制T细胞的免疫杀伤作用,从而发挥免疫抑制作用(Antonioli L,et al.NatRev Cancer.2013;13:842-857.)。CD73在人的B细胞、T细胞、骨髓细胞、骨髓基质细胞及胸腺上皮细胞均表达。
器官纤维化是指由于各种慢性刺激因素,如病原微生物感染、炎症、免疫反应、毒素(药物)、放射线、缺血及血流动力学改变等,导致器官实质细胞发生坏死,纤维结缔组织,包括细胞成分和细胞外基质(extracellular matrix,ECM)异常增多和过度沉积的病理过程。此外,还有一些致病机理不明的器官纤维化,称为特发性或原发性器官纤维化,如特发性肺纤维化(Idiopathic Pulmonary Fibrosis,IPF)等。程度较轻者称为纤维化,重者引起组织结构破坏而发生器官硬化(organ scarring)。纤维化器官其组织内沉积的纤维结缔组织包括细胞成分和ECM两大部分。组织的实质细胞、成纤维细胞和单核吞噬细胞等;以及胶原、非胶原糖蛋白、蛋白聚糖和弹性纤维等。
参与器官纤维化形成的常见细胞因子最重要的是转化生长因子-βTGF-β(transforming growth factor-β)(Meng XM,Nikolic-Paterson DJ,Lan HY.Nat RevNephrol.2016;12(6):325-338.)。此外,其它细胞因子如结缔组织生长因子CTGF(connective tissue growth factor)、血小板源性生长因子PDGF(platelet-direvedgrowth actor)、碱性纤维母细胞生长因子bFGF(basic fibroblast growth factor)、表皮生长因子EGF(epidermal growth factor)和IL-1、IL-6、IL-8、TNF-α、IFN-γ等也参与疾病的发生(Wynn TA.J Pathol.2008;214(2):199-210)。
研究证实,CD73-腺苷信号通路的激活可以刺激产生TGF-β,并通过TGF-β的自分泌活性维持CD73表达(García-Rocha R et al.Cytokine.2019;118:71-79.),而TGF-β信号通过腺苷依赖性机制调节乳腺癌的ECM沉积(Vasiukov G,et al.Cancer Res.2020;80(12):2628-2638)。
组织血运障碍是器官纤维化发生的危险因素,而器官纤维化导致的机构改变又常可导致组织血运障碍,出现组织细胞缺氧,在这种状态下低氧诱导因子-1(HIF-1)等分子的上调,导致CD73广泛表达(Synnestvedt K,et al.J Clin Invest.2002;110:993-1002)。此外,A2B受体(A2BR)在低氧状态下更容易激活,A2BR的激活直接促进了相关细胞产生大量IL-6,不但可以诱导肺纤维细胞的分化(Zhong HY et al.Am J Respir Cell Mol Biol,2005,32:2-8.)。
器官纤维化可发生在多种组织,如肝、肾、心脏、肺及骨髓等。
慢性肾脏病的主要病理特征为细胞外基质过度沉积,广泛的纤维化。最终导致终末肾功能衰竭的共同通路。肾纤维化的范围和程度与肾功能缺陷具有高度的相关性。
肝纤维化常见于肝脏炎症感染(病毒、细菌、真菌、寄生虫)、毒素损害、肝血流改变、许多先天性代谢异常引起物质在肝脏贮积,上述因素都可导致肝纤维化,损害肝脏功能。
骨髓纤维化表现为骨髓中胶原、纤维连接蛋白、层粘连蛋白等纤维组织的异常沉积,代替正常的骨髓造血组织,从而严重影响造血功能。
心肌的进行纤维化伴随心肌(心室)重构和心脏功能减退。动脉硬化是动脉纤维增性病变,导致血管壁增厚、僵硬而失去弹性和管腔变小。
肺纤维化病理过程是肺组织损伤修复失调导致大量细胞外基质重构、过度沉积,最终导致肺组织结构改变和功能丧失。其中,特发性肺纤维化(idiopathic pulmonaryfibrosis,IPF)是一种病因和发病机制尚不明确的、慢性进行性纤维化性间质性肺疾病。病变主要局限于肺部,好发于中老年男性,主要表现为进行性加重的呼吸困难,伴限制性通气功能障碍和气体交换障碍,导致低氧血症、甚至呼吸衰竭。研究发现,特发性肺纤维化与腺苷系统存在潜在的联系。CD73催化AMP生成腺苷,腺苷与受体A2BR结合,促进肺成纤维细胞分化为肌纤维细胞(Della LV et al.Pharmacological research,2013,76:182-189.)。动物实验中,CD73缺失的小鼠与野生型小鼠相比,放疗诱导的肺纤维化程度较轻(WirsdorferF.et al.Cancer research,2016,76(10):3045-3056.);选择性拮抗A2BR,可以减轻炎症及纤维化过程(Zhou Y et al.PloS one,2010,5(2):e9224)。
发明内容
本发明人利用哺乳动物细胞表达系统表达出重组的人CD73作为抗原免疫小鼠,经小鼠脾脏细胞与骨髓瘤细胞融合获得杂交瘤细胞。发明人通过对大量样本的筛选,得到了杂交瘤细胞株LT014(保藏编号为CCTCC NO:C2018137)。
本发明人惊奇地发现,杂交瘤细胞株LT014能够分泌产生与人CD73特异性结合的特异性单克隆抗体(命名为19F3),进一步地,本发明人制得了抗人CD73的人源化抗体(例如命名为19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM))。
本发明人还惊奇地发现,本发明的抗体例如19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM)能够十分有效地以非底物竞争的方式抑制CD73的酶活反应,降低腺苷的产生,并且在小鼠肺纤维化模型中展现出良好的药理学活性。本发明的抗体具有用于治疗组织器官纤维化的效果。
本发明的另一个方面还涉及一种抗CD73抗体,其中,所述抗CD73抗体包含SEQ IDNO:2、SEQ ID NO:6或SEQ ID NO:10所示重链可变区的HCDR1,HCDR2和HCDR3,和SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14所示的轻链可变区的LCDR1,LCDR2和LCDR3;
优选地,根据IMGT编号系统,所述抗CD73抗体包含:
HCDR1,其包含SEQ ID NO:15所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
HCDR2,其包含SEQ ID NO:16所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
HCDR3,其包含SEQ ID NO:17所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
LCDR1,其包含SEQ ID NO:18所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
LCDR2,其包含SEQ ID NO:19所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,和
LCDR3,其包含SEQ ID NO:20所示的氨基酸序列,与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成。
在本发明的一些实施方案中,所述抗体的重链可变区包含下述序列,或由下述序列组成:
所述抗体的重链可变区包含下述序列,或由下述序列组成:
SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10,与SEQ ID NO:2、SEQ ID NO:6或SEQID NO:10具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与SEQ ID NO:2、SEQID NO:6或SEQ ID NO:10所示的氨基酸序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;并且
所述抗体的轻链可变区包含下述序列,或由下述序列组成:
SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14,与SEQ ID NO:4、SEQID NO:8、SEQ ID NO:12或SEQ ID NO:14具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14所示的氨基酸序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列。
在本发明的一些实施方案中,所述抗体的重链可变区的氨基酸序列如SEQ ID NO:2所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:4所示;
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:6所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:8所示;
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:10所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:12所示;或
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:10所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:14所示。
在本发明的一些实施方案中,所述抗体的重链恒定区为Ig gamma-1链C区,ACCESSION:P01857;轻链恒定区为Ig kappa链C区,ACCESSION:P01834。
在本发明的一些实施方案中,所述抗体的重链恒定区为在Ig gamma-1链C区,ACCESSION:P01857的基础上在第234号位点引进了亮氨酸到丙氨酸的点突变(L234A),第235号位点引进了亮氨酸到丙氨酸的点突变(L235A);轻链恒定区为Ig kappa链C区,ACCESSION:P01834,氨基酸序列如SEQ ID NO:21所示。
轻链和重链的可变区决定抗原的结合;每条链的可变区均含有三个高变区,称互补决定区(CDR)(重链(H)的CDR包含HCDR1、HCDR2、HCDR3,轻链(L)的CDR包含LCDR1、LCDR2、LCDR3;其由Kabat等人命名,见Bethesda M.d.,Sequences of Proteins ofImmunological Interest,Fifth Edition,NIH Publication 1991;1-3:91-3242。
优选地,CDR也可以由IMGT编号系统定义,请参见Ehrenmann,Francois,QuentinKaas,and Marie-Paule Lefranc.IMGT/3Dstructure-DB and IMGT/DomainGapAlign:adatabase and a tool for immunoglobulins or antibodies,T cell receptors,MHC,IgSF and MhcSF.Nucleic acids research 2009;38(suppl_1):D301-D307。
通过本领域技术人员所熟知的技术手段,例如通过VBASE2数据库根据IMGT定义分析单克隆抗体序列的CDR区的氨基酸序列。
在已知抗体重链和轻链可变区序列的情况下,目前有几种确定抗体CDR区的方法,包括Kabat,IMGT,Chothia和AbM编号系统。
然而,每种关于抗体或其变体的CDR的定义的应用都将在本文定义和使用的术语的范围内。如果给定该抗体的可变区氨基酸序列,则本领域技术人员通常可确定哪些残基包含特定CDR,而不依赖于该序列自身之外的任何实验数据。
本发明涉及的抗体19F3、19F3H1L1(hG1DM)、19F3H2L2(hG1DM)、19F3H2L3(hG1DM)具有相同的CDR:
其重链可变区的3个CDR区的氨基酸序列如下:
HCDR1:GYSFTGYT(SEQ ID NO:15),
HCDR2:INPYNAGT(SEQ ID NO:16),
HCDR3:ARSEYRYGGDYFDY(SEQ ID NO:17);
其轻链可变区的3个CDR区的氨基酸序列如下:
LCDR1:QSLLNSSNQKNY(SEQ ID NO:18),
LCDR2:FAS(SEQ ID NO:19),
LCDR3:QQHYDTPYT(SEQ ID NO:20)。
在本发明的一些实施方案中,所述抗体为单克隆抗体。
在本发明的一些实施方案中,所述抗体为人源化抗体、嵌合抗体、多特异性抗体(例如双特异性抗体)。
在本发明的一些实施方式中,所述抗原结合片段选自Fab、Fab′、F(ab′)2、Fd、Fv、dAb、Fab/c、互补决定区片段、单链抗体(例如,scFv)、人源化抗体、嵌合抗体或双特异性抗体。
本发明的另一个方面涉及分离的多肽,其选自以下各项组成的组:
(1)分离的多肽,其包含SEQ ID NO:15,SEQ ID NO:16和SEQ ID NO:17所示的序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:18;SEQ ID NO:19;SEQ ID NO:20所示的序列;
(2)分离的多肽,其包含SEQ ID NO:18;SEQ ID NO:19;SEQ ID NO:20所示的序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:15,SEQ ID NO:16和SEQ ID NO:17所示的序列;
(3)分离的多肽,其包含SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还分别对应包含SEQ ID NO:4、SEQ ID NO:8或SEQ ID NO:12所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(4)分离的多肽,其包含SEQ ID NO:4、SEQ ID NO:8或SEQ ID NO:12所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还分别对应包含SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(5)分离的多肽,其包含SEQ ID NO:10所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:14所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(6)分离的多肽,其包含SEQ ID NO:14所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:10所示的序列或与所述序列具有至少80%,81%,82%,83%,84%,85%,86%、87%、88%、89%、90%,优选至少91%,92%,93%,94%,95%,96%,97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列。
本发明的另一方面涉及一种分离的核酸分子,其编码本发明任一项所述的抗体或其抗原结合片段,或所述分离的多肽。
本发明的再一方面涉及一种载体,其包含本发明的分离的核酸分子。
本发明的再一方面涉及一种宿主细胞,其包含本发明的分离的核酸分子,或者本发明的载体。
本发明的再一方面涉及一种偶联物,其包括抗体以及偶联部分,其中,所述抗体为本发明任一项所述的抗体或其抗原结合片段,所述偶联部分为纯化标签(如His标签),可检测的标记或小分子药物;优选地,所述偶联部分为放射性同位素、荧光物质、化学发光物质、有色物质、聚乙二醇或酶;优选地,所述小分子药物为小分子细胞毒药物;更优选地,所述小分子药物为肿瘤化疗药物,更优选地,所述抗体或其抗原结合片段通过连接子与小分子药物连接;例如,所述连接子为腙键、二硫键或肽键;更优选地,所述抗体或其抗原结合片段与小分子药物以一定的摩尔比连接;例如,所述摩尔比为1∶(2-4),更优选地,所述小分子药物是抗纤维化药物。
本发明的再一个方面,涉及融合蛋白或多特异性抗体(优选双特异性抗体),其包含本发明任一项所述的抗体或其抗原结合片段。
本发明的再一方面涉及一种试剂盒,其包括本发明所述的抗体或其抗原结合片段、本发明的偶联物、融合蛋白或多特异性抗体;优选地,所述试剂盒还包括第二抗体,其特异性识别所述抗体;任选地,所述第二抗体还包括可检测的标记,例如放射性同位素、荧光物质、化学发光物质、有色物质或酶。
在本发明的再一个方面,涉及试剂盒,其包含有效量(例如0.001mg-1000mg)的本发明所述的抗体或其抗原结合片段、本发明的偶联物、融合蛋白或多特异性抗体,和任选地,还包含有效量的一种或多种抗纤维化药物(例如100-2400mg)。优选地,所述试剂盒还包含免疫抑制剂和/或抗炎剂和/或DNA甲基化调节剂。
在本发明的一些实施方案中,所述抗纤维化药物可以是RhoA、RhoAGTPases、TGF-β1或CTGF或RhoA信号通路的其它任何成员的调节剂,或者可以调节细胞因子信号传导抑制剂1(SOCS1)、细胞因子信号传导抑制剂3(SOCS 3)或TLR9的调节剂,尼达尼布,吡非尼酮,血管生成因子拮抗剂,抑制心肌重构的药物(如ACEI有卡托普利,依那普利,福辛普利,贝那普利,赖诺普利等;ARB类有氯沙坦,缬沙坦,奥美沙坦,厄贝沙坦,坎地沙坦等),β受体阻滞剂(如普萘洛尔,美托洛尔,阿替洛尔,比索洛尔,卡维地洛等),或者是他汀类化合物或其衍生物。优选地,所述他汀类药物选自洛伐他汀,普伐他汀,氟伐他汀,西立伐他汀,阿托伐他汀,辛伐他汀,匹伐他汀,罗苏伐他汀,或其组合。
本发明的再一方面涉及本发明任一项所述的抗体或其抗原结合片段、本发明的偶联物、融合蛋白或多特异性抗体在制备试剂盒中的用途,所述试剂盒用于检测CD73在样品中的存在或其水平。
本发明的再一方面涉及一种药物组合物,其包含本发明任一项所述的抗体或其抗原结合片段、本发明的偶联物、融合蛋白或多特异性抗体;可选地,所述药物组合物还包括药学上可接受的载体和/或赋形剂。优选地,所述药物组合物为适于通过皮下注射、皮内注射、静脉内注射、肌内注射或病灶内注射施用的形式。
本发明的再一方面涉及本发明所述的抗体或其抗原结合片段、所述的偶联物或所述的融合蛋白或多特异性抗体,用于治疗和/或预防组织器官纤维化,或在制备治疗和/或预防组织器官纤维化的药物或试剂盒中的用途。
本发明的再一方面涉及治疗和/或预防组织器官纤维化的方法,包括向受试者或患者施用有效量的所述的抗体或其抗原结合片段、所述的偶联物或所述的融合蛋白或多特异性抗体。
在本发明的一些实施方案中,所述组织器官纤维化选自:特发性肺纤维化;皮肤纤维化,例如硬皮病或外伤和手术后产生的皮肤瘢痕;眼纤维化,例如眼硬化症、结膜和角膜上的瘢痕以及结膜上生出的翼状胬肉;胰腺和肺的囊性纤维化;心内膜心肌纤维化;特发性心肌病;肝硬化;纵隔纤维化;进行性大块纤维化;增生性纤维化;肿瘤纤维化;肺结核导致的肺部的纤维化。在一些实施方案中,所述方法包括向受试者或患者同时或顺序施用抗纤维化药物(如他汀类药物),优选地,所述抗纤维化药物选自洛伐他汀,普伐他汀,氟伐他汀,西立伐他汀,阿托伐他汀,辛伐他汀,匹伐他汀,罗苏伐他汀,或其组合。
在一些实施方案中,本发明的抗体或其抗原结合片段、所述的抗体药物偶联物或者所述的双特异性抗体的有效量为0.001mg-1000mg,更优选0.001mg-900mg、0.001mg-800mg、0.001mg-700mg、0.001mg-600mg、0.001mg-500mg、0.001mg-400mg、0.001mg-300mg、0.001mg-200mg、0.001mg-100mg,最优选为100mg、200mg、300mg、400mg、500mg、600mg、700mg、800mg、900mg或1000mg,或者,基于受试者或患者的体重,所述有效量为0.1-100mg/kg,优选1-90mg/kg、1-80mg/kg、1-70mg/kg、1-60mg/kg、1-50mg/kg、1-40mg/kg、1-30mg/kg、1-20mg/kg或1-10mg/kg。在本发明的上述任一实施方案,一种或多种抗纤维化药物(例如上文所述的他汀类药物)的有效量为100-2400mg,优选100mg-2300mg、100mg-2200mg、100mg-2100mg、100mg-2000mg、100mg-1900mg、100mg-1800mg、100mg-1700mg、100mg-1600mg、100mg-1800mg、100mg-1800mg、100mg-1800mg、100mg-1800mg、100mg-1800mg,更优选为100mg,200mg,300mg,400mg,500mg,600mg,700mg,800mg,900mg,1000mg。或者,在本发明的上述任一实施方案中,基于受试者或患者的体重,所述抗纤维化药物的有效量为0.1-100mg/kg,优选1-90mg/kg、1-80mg/kg、1-70mg/kg、1-60mg/kg、1-50mg/kg、1-40mg/kg、1-30mg/kg、1-20mg/kg或1-10mg/kg。在本发明的另一个方面,涉及单次药物剂量单元,其包含0.001mg-1000mg的本发明的抗体或其抗原结合片段,优选0.001mg-900mg、0.001mg-800mg、0.001mg-700mg、0.001mg-600mg、0.001mg-500mg、0.001mg-400mg、0.001mg-300mg、0.001mg-200mg、0.001mg-100mg,更优选为100mg、200mg、300mg、400mg、500mg、600mg、700mg、800mg、900mg或1000mg的本发明的抗体或其抗原结合片段。
本发明的再一方面涉及杂交瘤细胞株LT014,其于2018年6月21日保藏在中国,武汉的中国典型培养物保藏中心(CCTCC),保藏编号为CCTCC NO:C2018137。
在一些实施方案中,所述的抗体或其抗原结合片段、偶联物、融合蛋白或多特异性抗体被给予(优选静脉给予)单次或多次。
在本发明中,除非另有说明,否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且,本文中所用的细胞培养、分子遗传学、核酸化学、免疫学实验室操作步骤均为相应领域内广泛使用的常规步骤。同时,为了更好地理解本发明,下面提供相关术语的定义和解释。
如本文中所使用的,术语EC50是指半最大效应浓度(concentration for 50%ofmaximal effect),是指能引起50%最大效应的浓度。
如本文中所使用的,术语“抗体”是指通常由两对多肽链(每对具有一条“轻”(L)链和一条“重”(H)链)组成的免疫球蛋白分子。抗体轻链可分类为κ和λ轻链。重链可分类为μ、δ、γ、α或ε,并且分别将抗体的同种型定义为IgM、IgD、IgG、IgA和IgE。在轻链和重链内,可变区和恒定区通过大约12或更多个氨基酸的“J”区连接,重链还包含大约3个或更多个氨基酸的“D”区。各重链由重链可变区(VH)和重链恒定区(CH)组成。重链恒定区由3个结构域(CH1、CH2和CH3)组成。各轻链由轻链可变区(VL)和轻链恒定区(CL)组成。轻链恒定区由一个结构域CL组成。抗体的恒定区可介导免疫球蛋白与宿主组织或因子,包括免疫系统的各种细胞(例如,效应细胞)和经典补体系统的第一组分(C1q)的结合。VH和VL区还可被细分为具有高变性的区域(称为互补决定区(CDR)),其间散布有较保守的称为构架区(FR)的区域。各VH和VL由按下列顺序:FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4从氨基末端至羧基末端排列的3个CDR和4个FR组成。各重链/轻链对的可变区(VH和VL)分别形成抗原结合部位。氨基酸至各区域或结构域的分配遵循Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health,Bethesda M.d.(1987 and 1991)),或Chothia&LeskJ.Mol.Biol.1987;196:901-917;Chothia等人Nature 1989;342:878-883或者IMGT编号系统定义,见Ehrenmann,Francois,Quentin Kaas,and Marie-Paule Lefranc.″IMGT/3Dstructure-DB and IMGT/DomainGapAlign:a database and a tool forimmunoglobulins or antibodies,T cell receptors,MHC,IgSF and MhcSF.″Nucleicacids research 2009;38(suppl_1):D301-D307.的定义。术语“抗体”不受任何特定的产生抗体的方法限制。例如,其包括,特别地,重组抗体、单克隆抗体和多克隆抗体。抗体可以是不同同种型的抗体,例如,IgG(例如,IgG1,IgG2,IgG3或IgG4亚型),IgA1,IgA2,IgD,IgE或IgM抗体。
如本文中所使用的,术语“单抗”和“单克隆抗体”是指,来自一群高度同源的抗体分子中的一个抗体或抗体的一个片段,也即除可能自发出现的自然突变外,一群完全相同的抗体分子。单抗对抗原上的单一表位具有高特异性。多克隆抗体是相对于单克隆抗体而言的,其通常包含至少2种或更多种的不同抗体,这些不同的抗体通常识别抗原上的不同表位。单克隆抗体通常可采用Kohler等首次报道的杂交瘤技术获得(G,MilsteinC.Continuous cultures of fused cells secreting antibody of predefinedspecificity.nature,1975;256(5517):495),但也可采用重组DNA技术获得(如参见U.S.Patent 4,816,567)。
如本文中所使用的,术语“人源化抗体”是指,人源免疫球蛋白(受体抗体)的全部或部分CDR区被一非人源抗体(供体抗体)的CDR区替换后得到的抗体或抗体片段,其中的供体抗体可以是具有预期特异性、亲和性或反应性的非人源(例如,小鼠、大鼠或兔)抗体。此外,受体抗体的构架区(FR)的一些氨基酸残基也可被相应的非人源抗体的氨基酸残基替换,或被其他抗体的氨基酸残基替换,以进一步完善或优化抗体的性能。关于人源化抗体的更多详细内容,可参见例如,Jones et al.,Nature 1986;321:522-525;Reichmann etal.,Nature 1988;332:323-329;Presta,Curr.Op.Struct.Biol.,1992;2:593-596;和Clark M.Antibody humanization:a case of the‘Emperor’s new clothes’?[J].Immunol.Today,2000;21(8):397-402。
如本文中所使用的,术语“分离的”或“被分离的”指的是,从天然状态下经人工手段获得的。如果自然界中出现某一种“分离”的物质或成分,那么可能是其所处的天然环境发生了改变,或从天然环境下分离出该物质,或二者情况均有发生。例如,某一活体动物体内天然存在某种未被分离的多聚核苷酸或多肽,而从这种天然状态下分离出来的高纯度的相同的多聚核苷酸或多肽即称之为分离的。术语“分离的”或“被分离的”不排除混有人工或合成的物质,也不排除存在不影响物质活性的其它不纯物质。
如本文中所使用的,术语“载体(vector)”是指,可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时,载体称为表达载体。载体可以通过转化,转导或者转染导入宿主细胞,使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的,包括但不限于:质粒;噬菌粒;柯斯质粒;人工染色体,例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC);噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于,逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件,包括但不限于,启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外,载体还可含有复制起始位点。
如本文中所使用的,术语“宿主细胞”是指,可用于导入载体的细胞,其包括但不限于,如大肠杆菌或枯草杆菌等的原核细胞,如酵母细胞或曲霉菌等的真菌细胞,如S2果蝇细胞或Sf9等的昆虫细胞,或者如纤维原细胞,CHO细胞,COS细胞,NSO细胞,HeLa细胞,GS细胞,BHK细胞,HEK 293细胞或人细胞等的动物细胞。
如本文中使用的,术语“特异性结合”是指,两分子间的非随机的结合反应,如抗体和其所针对的抗原之间的反应。在某些实施方式中,特异性结合某抗原的抗体(或对某抗原具有特异性的抗体)是指,抗体以小于大约10-5M,例如小于大约10-6M、10-7M、10-8M、10-9M或10-10M或更小的亲和力(KD)结合该抗原。
如本文中所使用的,术语“KD”是指特定抗体-抗原相互作用的解离平衡常数,其用于描述抗体与抗原之间的结合亲和力。平衡解离常数越小,抗体-抗原结合越紧密,抗体与抗原之间的亲和力越高。通常,抗体以小于大约10-5M,例如小于大约10-6M、10-7M、10-8M、10- 9M或10-10M或更小的解离平衡常数(KD)结合抗原(例如,PD-1蛋白)。可以使用本领域技术人员知悉的方法测定KD,例如使用Fortebio分子相互作用仪测定。
如本文中所使用的,术语“单克隆抗体”和“单抗”具有相同的含义且可互换使用;术语“多克隆抗体”和“多抗”具有相同的含义且可互换使用;术语“多肽”和“蛋白质”具有相同的含义且可互换使用。并且在本发明中,氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如,丙氨酸可用A或Ala表示。
如本文中所使用的,术语“药学上可接受的载体和/或赋形剂”是指在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂,其是本领域公知的(参见例如Remington′s Pharmaceutical Sciences.Edited by Gennaro AR,19thed.Pennsylvania:Mack Publishing Company,1995),并且包括但不限于:pH调节剂,表面活性剂,佐剂,离子强度增强剂。例如,pH调节剂包括但不限于磷酸盐缓冲液;表面活性剂包括但不限于阳离子,阴离子或者非离子型表面活性剂,例如Tween-80;离子强度增强剂包括但不限于氯化钠。
在本发明中,术语“单次药物剂量单元”表示在给药方案的时刻待给药于受试者或患者的本发明所述的抗体或其抗原结合片段、所述的抗体药物偶联物或者所述的双特异性抗体(或包含其的药物组合物)的单次药物剂型,如以一个安瓿瓶为单位。如本文中所使用的,术语“有效量”是指足以获得或至少部分获得期望的效果的量。例如,预防疾病(例如本发明所述的组织器官纤维化)有效量是指,足以预防,阻止,或延迟疾病的发生的量;治疗疾病有效量是指,足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。
发明的有益效果:
本发明的单克隆抗体能够很好地特异性与CD73结合,并且能够十分有效地、以非底物竞争的方式抑制CD73的酶活反应,可以有效治疗组织器官纤维化疾病。
附图说明
图1.MDA-MB-231细胞中加入抗CD73抗体的酶活性的检测结果。
图2. 19F3H2L3(hG1DM)对hCD73转基因小鼠肺纤维化模型增强呼气间歇值相对基线的变化率的影响。数据以“平均值±标准误差”表示;增强呼气间歇值抑制率%=[100-(T/C*100)]/100×100%,其中T和C分别是给药组及同型对照组的增强呼气间歇值相对基线的变化率-Mch浓度曲线下面积。
图3. 19F3H2L3(hG1DM)对hCD73转基因小鼠肺纤维化模型肺泡灌洗液炎症细胞总数的影响。*P<0.05,**P<0.01,***P<0.001,VS正常组;#P<0.05,##P<0.01,###P<0.001,vs同型对照组(t-test)。
图4. 19F3H2L3(hG1DM)对hCD73转基因小鼠肺纤维化模型肺泡灌洗液炎症细胞数的影响。*P<0.05,**P<0.01,***P<0.001,VS正常组;#P<0.05,##P<0.01,###P<0.001,vs同型对照组(t-test)。
图5.19F3H2L3(hG1DM)对hCD73转基因小鼠肺纤维化模型肺组织匀浆中羟脯氨酸(HYP)含量的影响。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述。本领域技术人员将会理解,下面的实施例仅用于说明本发明,而不应视为限定本发明的范围。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件(例如参考J.萨姆布鲁克等著,黄培堂等译的《分子克隆实验指南》,第三版,科学出版社)或按照产品说明书进行。所用试剂或仪器未注明生产厂商者,为可以通过市场购买获得的常规产品。例如MDA-MB-231细胞和U87-MG细胞可以购自ATCC;
在本发明的下述实施例中,使用的BALB/c小鼠购自广东省医学实验动物中心;
在本发明的下述实施例中,使用的hCD73转基因小鼠购自江苏百奥赛图实验动物有限公司;
在本发明的下述实施例中,所用的阳性对照抗体MEDI9447(Oleclumab),生产自中山康方生物医药有限公司,其序列与Medlmmune Limited在WHO药物信息数据库及相关专利中所公开的Oleclumab氨基酸序列全长一致(https://www.who.int/medicines/publications/drμginformation/innlists/en/),在本发明实施例中标记为MEDI9447或者MEDI9447(Akeso);
在本发明的下述实施例中,所用的同型对照抗体为人抗鸡蛋溶酶体抗体(humananti-Hen Egg Lysozyme IgG,即anti-HEL抗体,或者human IgG,简称hIgG,或者同型对照)的序列来自于Acierno等人发表的Affinity maturation increases the stability andplasticity of the Fv domain of anti-protein antibodies中Fab F10.6.6序列的可变区序列(Acierno等人.J Mol Biol.2007;374(1):130-146.);
在本发明的下述实施例中,所用的牛血清白蛋白(BSA)来源于Sigma,货号:V900933-1KG;
在本发明的下述实施例中,所用的RPMI 1640来源于Gibco,货号:22400-089;
在本发明的下述实施例中,所用的胎牛血清来源于Excell bio,货号:FSP500;
在本发明的下述实施例中,所用的丙酮酸钠来源于Gibco,货号:11360-070;
在本发明的下述实施例中,所用的非必需氨基酸来源于Gibco,货号:11140-050;
在本发明的下述实施例中,所用的L-谷氨酰胺来源于Gibco,货号:25030-081。
在本发明的下述实施例中,所用的MDA-MB-231来源于ATCC,货号:HTB-26;
在本发明的下述实施例中,所用的博来霉素来源于瀚晖制药有限公司,货号:19012311;
在本发明的下述实施例中,所用的台盼蓝来源于Sigma;批号:MKCF8888;货号:T6146;
在本发明的下述实施例中,所用的磷酸盐缓冲液来源于福州迈新生物技术开发有限公司;
在本发明的下述实施例中,所用的乙酰甲胆碱来源于sigma;批号:MKCF3289;货号:A2251;
在本发明的下述实施例中,所用的羟脯氨酸来源于hydroxyproline,HYP;检测试剂盒来源于QuiekZyme Biosciences,货号:QZBTOTCOL1;
在本发明的下述实施例中,所用的舒泰来源于法国维克有限公司Virbac S.A,货号:BN 6ALU;
在本发明的下述实施例中,所用的异氟烷来源于深圳瑞沃德生命科技有限公司;
在本发明的下述实施例中,所用的氯化钠注射液来源于江西科伦药业有限公司。
在本发明的下述实施例中,所用的CD73(5′-核酸酶)特异性抑制剂APCP(alpha,beta-methylene adenosine-5′-diphosphate,5’-α,β-亚甲基-二磷酸腺苷)来源于sigma,货号:M3763-10MG。
实施例1:抗CD73抗体19F3的制备
1、杂交瘤细胞株LT014的制备
制备抗CD73抗体所用的抗原为人NT5E-His(NT5E为GenbankID:NP_002517.1,位置:1-552)。取免疫后的小鼠的脾细胞与小鼠骨髓瘤细胞融合,制成杂交瘤细胞。以人NT5E(NT5E为GenbankID:NP_002517.1,位置:1-552)-Biotin作为抗原,对杂交瘤细胞进行间接ELISA法筛选,获得能够分泌与CD73特异性结合的抗体的杂交瘤细胞。对筛选得到的杂交瘤细胞,经过有限稀释法得到稳定的杂交瘤细胞株。将以上杂交瘤细胞株命名为杂交瘤细胞株LT014,其分泌的单克隆抗体命名为19F3。
杂交瘤细胞株LT014(又称CD73-19F3),其于2018年6月21日保藏于中国典型培养物保藏中心(CCTCC),保藏编号为CCTCC NO:C2018137,保藏地址为中国.武汉.武汉大学,邮编:430072。
2、抗CD73抗体19F3的制备
用CD培养基(Chemical Defined Medium)对上面制得的LT014细胞株进行培养(CD培养基,内含1%青链霉素,于5%CO2,37℃细胞培养箱中进行培养)。7天后收集细胞培养上清,通过高速离心、微孔滤膜抽真空过滤,并使用HiTrap proteinAHP柱进行纯化,制得抗体19F3。
实施例2:抗CD73的抗体19F3的序列分析
按照培养细胞细菌总RNA提取试剂盒(Tiangen,货号DP430)的方法,从实施例1中培养的LT014细胞株中提取mRNA。
PCR扩增产物直接进行TA克隆,具体操作参考pEASY-T1 Cloning Kit(TransgenCT101)试剂盒说明书进行。
将TA克隆的产物直接进行测序,测序结果如下:
重链可变区的核酸序列如SEQ ID NO:1所示,片段长351bp。
其编码的氨基酸序列为SEQ ID NO:2所示,长度为117个氨基酸;
其中重链CDR1的序列如SEQ ID NO:15所示,重链CDR2的序列如SEQ ID NO:16所示,重链CDR3的序列如SEQ ID NO:17所示。
轻链可变区的核酸序列如SEQ ID NO:3所示,长度为321bp。
其编码的氨基酸序列为SEQ ID NO:4所示,长度为107个氨基酸;
其中轻链CDR1的序列如SEQ ID NO:18所示,轻链CDR2的序列如SEQ ID NO:19所示,轻链CDR3的序列如SEQ ID NO:20所示。
实施例3:抗人CD73的人源化抗体的轻链和重链设计和制备
1.抗人CD73的人源化抗体19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM)的轻链和重链设计
根据人CD73蛋白的三维晶体结构(Hage T,Reinemer P,Sebald W.Crystals of a1∶1 complex between human interleukin-4 and the extracellular domain of itsreceptor alpha chain.Eur J Biochem.1998;258(2):831-6.)以及实施例2获得的抗体19F3的序列,通过计算机模拟抗体模型,根据模型设计突变,得到抗体19F3H1L1(hG1DM)、19F3H2L2(hG1DM)、19F3H2L3(hG1DM)的可变区序列。
设计的可变区序列如下:
(1)人源化单克隆抗体19F3H1L1(hG1DM)的重链可变区和轻链可变区序列
重链可变区的核酸序列如SEQ ID NO:5所示,长度为363bp。
其编码的氨基酸序列如SEQ ID NO:6所示,长度为121aa,其中重链CDR1的序列如SEQ ID NO:15所示,重链CDR2的序列如SEQ ID NO:16所示,重链CDR3的序列如SEQ ID NO:17所示。
轻链可变区的核酸序列如SEQ ID NO:7所示,长度为339bp。
其编码的氨基酸序列如SEQ ID NO:8所示,长度为113aa,其中轻链CDR1的序列如SEQ ID NO:18所示,轻链CDR2的序列如SEQ ID NO:19所示,轻链CDR3的序列如SEQ ID NO:20所示。
(2)人源化单克隆抗体19F3H2L2(hG1DM)的重链可变区和轻链可变区序列
重链可变区的核酸序列如SEQ ID NO:9所示,长度为363bp。
其编码的氨基酸序列如SEQ ID NO:10所示,长度为121aa,其中重链CDR1的序列如SEQ ID NO:15所示,重链CDR2的序列如SEQ ID NO:16所示,重链CDR3的序列如SEQ ID NO:17所示。
轻链可变区的核酸序列如SEQ ID NO:11所示,长度为339bp。
其编码的氨基酸序列如SEQ ID NO:12所示,长度为113aa,其中轻链CDR1的序列如SEQ ID NO:18所示,轻链CDR2的序列如SEQ ID NO:19所示,轻链CDR3的序列如SEQ ID NO:20所示。
(3)人源化单克隆抗体19F3H2L3(hG1DM)的重链可变区和轻链可变区序列
重链可变区的核酸序列如SEQ ID NO:9所示,长度为363bp。
其编码的氨基酸序列如SEQ ID NO:10所示,长度为121aa,其中重链CDR1的序列如SEQ ID NO:15所示,重链CDR2的序列如SEQ ID NO:16所示,重链CDR3的序列如SEQ ID NO:17所示。
轻链可变区的核酸序列如SEQ ID NO:13所示,长度为339bp。
其编码的氨基酸序列如SEQ ID NO:14所示,长度为113aa,其中轻链CDR1的序列如SEQ ID NO:18所示,轻链CDR2的序列如SEQ ID NO:19所示,轻链CDR3的序列如SEQ ID NO:20所示。
2.人源化抗体19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM)的制备
19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM)的抗体的轻链恒定区为Ig kappa链C区,ACCESSION:P01834,见SEQ ID NO:22。
重链恒定区在Ig gamma-1 chain C region,ACCESSION:P01857的基础上,在第234号位点引进了亮氨酸到丙氨酸的点突变(L234A),第235号位点引进了亮氨酸到丙氨酸的点突变(L235A),获得了命名为19F3H1L1(hG1DM)、19F3H2L2(hG1DM)和19F3H2L3(hG1DM)的人源化抗体,见SEQ ID NO:21。
将19F3H1L1(hG1DM)重链cDNA和轻链的cDNA、19F3H2L2(hG1DM)重链cDNA和轻链的cDNA、以及19F3H2L3(hG1DM)的重链cDNA和轻链的cDNA,分别克隆到pUC57simple(金斯瑞公司提供)载体中,分别获得pUC57simple-19F3H1(hG1DM)、pUC57simple-19F3L1;pUC57simple-19F3H2(hG1DM)、pUC57simple-19F3L2和pUC57simple-19F3L3。参照《分子克隆实验指南(第二版)》介绍的标准技术,EcoRI&HindIII酶切合成的重、轻链全长基因,通过限制酶(EcoRI&HindIII)的酶切亚克隆到表达载体pcDNA3.1中获得表达质粒pcDNA3.1-19F3H1(hG1DM),pcDNA3.1-19F3L1,pcDNA3.1-19F3H2(hG1DM),pcDNA3.1-19F3L2,和pcDNA3.1-19F3L3,并进一步对重组表达质粒的重/轻链基因进行测序分析。随后将含有相应的轻、重链重组质粒设计基因组合(pcDNA3.1-19F3H1(hG1DM)/pcDNA3.1-19F3L1,pcDNA3.1-19F3H2(hG1DM)/pcDNA3.1-19F3L2,和pcDNA3.1-19F3H2(hG1DM)/pcDNA3.1-19F3L3)分别共转染293F细胞后收集培养液进行纯化。测序验证正确后,制备去内毒素级别的表达质粒并将质粒瞬时转染HEK293细胞进行抗体表达,培养7天后收集细胞培养液,采用Protein A柱进行亲和纯化获得人源化抗体。
实施例4:抗CD73抗体对抑制细胞内源表达CD73酶活性的检测
1、抗CD73抗体对MDA-MB-231细胞内源表达CD73酶活性的抑制活性检测
实验步骤如下:取状态良好的对数期MDA-MB-231细胞,用无血清的RPMI-1640培养液将细胞重悬、计数;将MDA-MB-231细胞接种至96孔板,3*104个细胞/100μl/孔;用无血清RPMI-1640培养液稀释抗体,起始浓度200μg/ml,按2.5倍进行梯度稀释;将抗体加入96孔板,每孔50μl,37℃孵育1小时。1小时后,每孔加入50μl RPMI-1640稀释的600μM AMP;3小时后取25μl细胞培养液上清,转移至新96孔板,每孔加入25μl 100μM的ATP;和50μl CTG(CellTiter-One Solution Assay,promega,Cat:G8461)显色液,进行显色,多标记微孔板检测仪(PerkinElmer 2140-0020)读取数据。同型对照抗体及CD73特异性抑制剂APCP分别作为阴性对照及阳性对照。
实验结果:结果如图1所示,19F3、19F3H2L3(hG1DM)、19F3H2L3(hG1DM)和19F3H2L3(hG1DM)均可呈剂量依赖性抑制MDA-MB-231内源表达的CD73酶催化AMP为腺苷A的活性,从而剂量依赖性降低产生的平均萤光强度RLU。
以上实验结果说明加入的AMP在无CD73抗体处理情况下,可被MDA-MB-231内源表达于细胞表面的CD73酶催化而转化为腺苷,从而解除对荧光素酶活性的抑制。而加入抗体后,由于CD73被抗体结合,而降低了其酶催化活性,使AMP不能转化为腺苷。提示抗CD73抗体以非底物竞争的方式有效抑制CD73的酶活反应,降低腺苷的产生。
实施例5:19F3H2L3(hG1DM)有效缓解博来霉素诱导的hCD73转基因小鼠肺纤维化
为了考察19F3H2L3(hG1DM)治疗肺纤维化的体内药效学,本实验采用博来霉素诱导的hCD73转基因小鼠肺纤维化模型,测定19F3H2L3(hG1DM)干预后小鼠的肺功能和肺泡灌洗液炎症细胞数。
实验步骤:实验第1天,动物异氟烷麻醉后将通过气管内的给药途径给予2U/kg博来霉素,实验第2天开始给药,每三天给药一次直至实验结束,具体的给药方案请见表2所示。
表2实验方案
在第21天,所有动物使用WBP系统对实验小鼠进行气道高反应性测定,即小鼠雾化吸入PBS溶液,随后将连续雾化吸入浓度为1.5625、3.125、6.25、12.5、25和50mg/mL的乙酰甲胆碱(Mch),测定相应浓度下的增强呼气间歇值,每个浓度下刺激90秒,绘制增强呼气间歇值相对基线的变化率-Mch浓度曲线,并计算曲线下面积。
肺功能检测完成后,异氟烷麻醉后眼眶采血约200微升,完成血样收集后,使用舒泰(腹腔注射,25-50mg/kg)对动物麻醉后进行气管插管,用0.8mL的PBS(包含1%BSA和0.6mM EDTA)对肺进行第一次灌洗。另取0.8mL的PBS(包含1%BSA和10mM EDTA)对肺进行第二次灌洗。4℃下300g离心BALF 5分钟,然后用1.5mL PBS将离心后获得的细胞团重悬用以涂片制备。使用血细胞分离器计算BALF中的细胞总数,使用Wright-Giemsa染色液染色,从而区分出嗜酸细胞,中性白细胞,巨噬细胞和淋巴细胞。在光学显微镜下计数。收集剩余BALF液体。灌洗后,通过脱颈椎安乐死动物,收集肺组织,冷冻保存于-80℃,用于匀浆后的羟脯氨酸含量检测。羟脯氨酸含量检测使用羟脯氨酸(hydroxyproline,HYP)检测试剂盒(QuiekZyme Biosciences),依照试剂盒说明书完成。实验数据表示成均数±标准误(Mean±SEM)表示,组间比较采用GraphPad统计学处理软件处理后,进行单因素方差分析或t-test评价结果,P<0.05有显著性差异,P<0.01有非常显著性差异。
结果如图2所示,在分组后第21天,与模型-同型对照组,即人IgG1同型对照抗体组,相比,19F3H2L3(hG1DM)高剂量组和低剂量组均能够抑制增强呼气间歇值相对基线的变化率,19F3H2L3(hG1DM)高剂量组和低剂量组对增强呼气间歇值相对基线的变化率-Mch浓度曲线下面积抑制率分别为21.05%、29.05%。19F3H2L3(hG1DM)对此模型的气道反应性有治疗作用。
结果如图3和图4所示,在实验结束时,hCD73转基因小鼠肺纤维化模型19F3H2L3(hG1DM)高剂量组和低剂量组肺泡灌洗液中炎症细胞总数相比同型对照组均显著降低(P<0.001),其中19F3H2L3(hG1DM)-高剂量组肺泡灌洗液中嗜酸性粒细胞(P<0.05)、中性粒细胞(P<0.05)和淋巴细胞(P<0.001)的数量相对同型对照组显著降低,19F3H2L3(hG1DM)-低剂量组肺泡灌洗液中中性粒细胞(P<0.05)和淋巴细胞(P<0.001)的数量相对同型对照组显著降低。
结果如图5显示,19F3H2L3(hG1DM)高剂量组和19F3H2L3(hG1DM)低剂量组与模型-同型对照组相比均降低了小鼠肺组织匀浆中羟脯氨酸的含量,19F3H2L3(hG1DM)低剂量组显示出了有统计学意义的降低。
Claims (20)
1.抗CD73(例如人CD73)抗体或其抗原结合片段,其中,所述抗CD73抗体包含SEQ IDNO:2、SEQ ID NO:6或SEQ ID NO:10所示重链可变区的HCDR1,HCDR2和HCDR3,和SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14所示的轻链可变区的LCDR1,LCDR2和LCDR3;
优选地,根据IMGT编号系统,所述抗CD73抗体包含:
HCDR1,其包含SEQ ID NO:15所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
HCDR2,其包含SEQ ID NO:16所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
HCDR3,其包含SEQ ID NO:17所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
LCDR1,其包含SEQ ID NO:18所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,
LCDR2,其包含SEQ ID NO:19所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%,98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成,和
LCDR3,其包含SEQ ID NO:20所示的氨基酸序列,与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1个、2个或3个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,或由其组成。
2.权利要求1所述的抗CD73抗体或其抗原结合片段,所述抗体的重链可变区包含下述序列,或由下述序列组成:
SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10,与SEQ ID NO:2、SEQ ID NO:6或SEQ IDNO:10具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10所示的氨基酸序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;并且
所述抗体的轻链可变区包含下述序列,或由下述序列组成:
SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14,与SEQ ID NO:4、SEQ IDNO:8、SEQ ID NO:12或SEQ ID NO:14具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与SEQ ID NO:4、SEQ ID NO:8、SEQ ID NO:12或SEQ ID NO:14所示的氨基酸序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列。
3.权利要求1或2所述的抗CD73抗体或其抗原结合片段,其中
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:2所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:4所示;
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:6所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:8所示;
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:10所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:12所示;或
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:10所示,并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:14所示。
4.权利要求1或2所述的抗CD73抗体或其抗原结合片段,其中所述抗体的重链恒定区为Ig gamma-1链C区,ACCESSION:P01857;轻链恒定区为Ig kappa链C区,ACCESSION:P01834。
5.权利要求1或2所述的抗CD73抗体或其抗原结合片段,其中所述抗体为单克隆抗体、人源化抗体、嵌合抗体、多特异性抗体(例如双特异性抗体)。
6.权利要求1或2所述的抗CD73抗体或其抗原结合片段,所述抗原结合片段选自Fab、Fab′、F(ab′)2、Fd、Fv、dAb、Fab/c、互补决定区片段、单链抗体(例如,scFv)、人源化抗体、嵌合抗体或双特异性抗体。
7.分离的多肽,其选自以下各项组成的组:
(1)分离的多肽,其包含SEQ ID NO:15,SEQ ID NO:16和SEQ ID NO:17所示的序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:18;SEQ ID NO:19;SEQ ID NO:20所示的序列;
(2)分离的多肽,其包含SEQ ID NO:18;SEQ ID NO:19;SEQ ID NO:20所示的序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:15,SEQID NO:16和SEQ ID NO:17所示的序列;
(3)分离的多肽,其包含SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还分别对应包含SEQ ID NO:4、SEQ ID NO:8或SEQ ID NO:12所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(4)分离的多肽,其包含SEQ ID NO:4、SEQ ID NO:8或SEQ ID NO:12所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还分别对应包含SEQ ID NO:2、SEQ ID NO:6或SEQ ID NO:10所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(5)分离的多肽,其包含SEQ ID NO:10所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:14所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列;
(6)分离的多肽,其包含SEQ ID NO:14所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列,其中所述多肽作为抗CD73抗体的一部分,特异性结合CD73,所述抗体还包含SEQ ID NO:10所示的序列或与所述序列具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%,优选至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列同一性的序列,或与所述序列相比具有一个或多个(优选1、2、3、4、5、6、7、8、9或10个)保守氨基酸突变(优选置换,插入或缺失)的氨基酸序列。
8.核酸分子,其编码权利要求1-6任一项所述的抗体或其抗原结合片段,或权利要求7所述分离的多肽。
9.载体,其包含权利要求8所述的核酸分子。
10.宿主细胞,其包含权利要求8所述的核酸分子,或权利要求9所述的载体。
11.偶联物,其包含权利要求1-6任一项所述的抗体或其抗原结合片段以及偶联部分,其中,所述偶联部分为纯化标签(如His标签),可检测的标记或小分子药物;优选地,所述偶联部分为放射性同位素、荧光物质、化学发光物质、有色物质、聚乙二醇或酶;优选地,所述小分子药物为小分子细胞毒药物;更优选地,所述小分子药物为肿瘤化疗药物,更优选地,所述抗体或其抗原结合片段通过连接子与小分子药物连接;例如,所述连接子为腙键、二硫键或肽键;更优选地,所述抗体或其抗原结合片段与小分子药物以一定的摩尔比连接;例如,所述摩尔比为1∶(2-4),更优选地,所述小分子药物是抗纤维化药物。
12.融合蛋白或多特异性抗体(优选双特异性抗体),其包含权利要求1-6任一项所述的抗体或其抗原结合片段。
13.试剂盒,其包括权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求11所述的偶联物或权利要求12所述的融合蛋白或多特异性抗体;优选地,所述试剂盒还包括第二抗体,所述第二抗体特异性识别所述抗体;任选地,所述第二抗体还包括可检测的标记,例如放射性同位素、荧光物质、化学发光物质、有色物质或酶;优选地,所述试剂盒用于检测CD73在样品中的存在或其水平。
14.药物组合物或单次药物剂量单元,其包含权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求11所述的偶联物或权利要求12所述的融合蛋白或多特异性抗体;可选地,所述药物组合物或单次药物剂量单元还包括药学上可接受的载体和/或赋形剂,优选地,所述药物组合物为适于通过皮下注射、皮内注射、静脉内注射、肌内注射或病灶内注射施用的形式。
15.权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求11所述的偶联物或权利要求12所述的融合蛋白或多特异性抗体,用于治疗和/或预防组织器官纤维化,或在制备治疗和/或预防组织器官纤维化的药物或试剂盒中的用途,优选地,所述组织器官纤维化选自:特发性肺纤维化;皮肤纤维化,例如硬皮病或外伤和手术后产生的皮肤瘢痕;眼纤维化,例如眼硬化症、结膜和角膜上的瘢痕以及结膜上生出的翼状胬肉;胰腺和肺的囊性纤维化;心内膜心肌纤维化;特发性心肌病;肝硬化;纵隔纤维化;进行性大块纤维化;增生性纤维化;肿瘤纤维化;肺结核导致的肺部的纤维化,优选地,所述试剂盒还包括治疗组织器官纤维化的药物。
16.治疗和/或预防组织器官纤维化的方法,包括向受试者或患者施用有效量的权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求11所述的偶联物或权利要求12所述的融合蛋白或多特异性抗体,优选地,所述组织器官纤维化选自:特发性肺纤维化;皮肤纤维化,例如硬皮病或外伤和手术后产生的皮肤瘢痕;眼纤维化,例如眼硬化症、结膜和角膜上的瘢痕以及结膜上生出的翼状胬肉;胰腺和肺的囊性纤维化;心内膜心肌纤维化;特发性心肌病;肝硬化;纵隔纤维化;进行性大块纤维化;增生性纤维化;肿瘤纤维化;肺结核导致的肺部的纤维化;更优选地,向所述受试者或患者同时或顺序施用抗纤维化药物,优选地,所述抗纤维化药物为RhoA、RhoAGTPases、TGF-β 1或CTGF或RhoA信号通路的其它任何成员的调节剂,或者可以调节细胞因子信号传导抑制剂1(SOCS1)、细胞因子信号传导抑制剂3(SOCS 3)或TLR9的调节剂,或者是他汀类化合物或其衍生物。优选地,所述他汀类药物选自洛伐他汀,普伐他汀,氟伐他汀,西立伐他汀,阿托伐他汀,辛伐他汀,匹伐他汀,罗苏伐他汀,或其组合。
17.权利要求16所述的方法,更优选地,所述抗体或其抗原结合片段、偶联物、融合蛋白或多特异性抗体的有效量为0.001mg-1000mg,更优选0.001mg-900mg、0.001mg-800mg、0.001mg-700mg、0.001mg-600mg、0.001mg-500mg、0.001mg-400mg、0.001mg-300mg、0.001mg-200mg、0.001mg-100mg,最优选为100mg、200mg、300mg、400mg、500mg、600mg、700mg、800mg、900mg或1000mg,或者,基于受试者或患者的体重,有效量为0.1-100mg/kg,优选1-90mg/kg、1-80mg/kg、1-70mg/kg、1-60mg/kg、1-50mg/kg、1-40mg/kg、1-30mg/kg、1-20mg/kg或1-10mg/kg。
18.权利要求16所述的方法,所述抗纤维化药物的有效量为100-2400mg,优选100mg-2300mg、100mg-2200mg、100mg-2100mg、100mg-2000mg、100mg-1900mg、100mg-1800mg、100mg-1700mg、100mg-1600mg、100mg-1800mg、100mg-1800mg、100mg-1800mg、100mg-1800mg、100mg-1800mg,更优选为100mg,200mg,300mg,400mg,500mg,600mg,700mg,800mg,900mg,1000mg,或者,基于受试者或患者的体重,所述抗纤维化药物的有效量为0.1-100mg/kg,优选1-90mg/kg、1-80mg/kg、1-70mg/kg、1-60mg/kg、1-50mg/kg、1-40mg/kg、1-30mg/kg、1-20mg/kg或1-10mg/kg。
19.杂交瘤细胞株,其选自:
LT014,其保藏于中国典型培养物保藏中心(CCTCC),保藏编号为CCTCC NO:C2018137。
20.权利要求16-18任一项所述的方法,其中权利要求1-6任一项所述的抗体或其抗原结合片段、权利要求11所述的偶联物或权利要求12所述的融合蛋白或多特异性抗体被给予(优选静脉给予)单次或多次。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011121211 | 2020-10-19 | ||
CN2020111212112 | 2020-10-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114380915A true CN114380915A (zh) | 2022-04-22 |
CN114380915B CN114380915B (zh) | 2024-03-22 |
Family
ID=81194459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110273227.3A Active CN114380915B (zh) | 2020-10-19 | 2021-03-12 | 抗cd73的抗体及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114380915B (zh) |
WO (1) | WO2022083049A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016075099A1 (en) * | 2014-11-10 | 2016-05-19 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
WO2019170131A1 (zh) * | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3383916T (pt) * | 2017-01-24 | 2022-03-30 | I Mab Biopharma Us Ltd | Anticorpos anti-cd73 e seus usos |
CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技(成都)有限公司 | 一种抗cd73单克隆抗体及其应用 |
-
2021
- 2021-03-12 CN CN202110273227.3A patent/CN114380915B/zh active Active
- 2021-03-12 WO PCT/CN2021/080517 patent/WO2022083049A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016075099A1 (en) * | 2014-11-10 | 2016-05-19 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
WO2019170131A1 (zh) * | 2018-03-07 | 2019-09-12 | 复旦大学 | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN114380915B (zh) | 2024-03-22 |
WO2022083049A1 (zh) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230340097A1 (en) | Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof | |
US20190321466A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
EP3309177A1 (en) | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof | |
KR20120044300A (ko) | 항-cd100 항체 및 이의 사용 방법 | |
WO2020168555A1 (zh) | Cd3抗原结合片段及其应用 | |
WO2022037531A1 (zh) | 抗cd73的抗体及其用途 | |
WO2016127912A1 (zh) | Pcsk9抗体、其药物组合物及其用途 | |
CN114380915B (zh) | 抗cd73的抗体及其用途 | |
KR20230004725A (ko) | 항-cd73 항체 및 이의 용도 | |
TW201942135A (zh) | 抗cd27 抗體、其抗原結合片段及其醫藥用途 | |
CA2875451A1 (en) | Antibody against transporter and use thereof | |
CN113015751A (zh) | 一种融合蛋白及其用途 | |
US11912777B2 (en) | Antibodies binding TNFR2 and uses thereof | |
WO2023001155A1 (zh) | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 | |
EP4234579A1 (en) | Anti-cd73 antibody and use thereof | |
US11629186B2 (en) | Anti-CCL8 antibodies and uses thereof | |
CN113164601B (zh) | 一种分离的抗原结合蛋白及其用途 | |
CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
CN114591428B (zh) | 抗Dsg1抗体及其应用 | |
WO2023246247A1 (zh) | 药物组合物及其用途 | |
WO2023241656A1 (zh) | 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |